Nanovibronix Inc
NAOV1.230USD
-0.199-13.99%
Close 05/16, 16:00（ET）Quotes delayed by 15 min
42.37KMarket Cap
LossP/E TTM
More Details of Nanovibronix Inc Company
NanoVibronix, Inc. is a medical device company focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The Company's primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use.
Company Info
Company codeNAOV
Company nameNanovibronix Inc
IPO dateApr 24, 2015
Founded at2003
CEOMr. Brian M. Murphy
Number of employees15
Security typeOrdinary Share
Fiscal year-endApr 24
Address969 Pruitt Ave,
CityTYLER
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77569
Phone19142333004
Websitehttps://nanovibronix.com/
Company codeNAOV
IPO dateApr 24, 2015
Founded at2003
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Christopher M. Fashek
Mr. Christopher M. Fashek
Independent Chairman of the Board
Independent Chairman of the Board
341.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
18.00
--
Dr. Martin S. Goldstein, M.D.
Dr. Martin S. Goldstein, M.D.
Independent Director
Independent Director
--
--
Mr. Thomas R. Mika
Mr. Thomas R. Mika
Independent Director
Independent Director
--
-100.00%
Mr. Brian M. Murphy
Mr. Brian M. Murphy
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Director
Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
348.00
--
Mr. Christopher M. Fashek
Mr. Christopher M. Fashek
Independent Chairman of the Board
Independent Chairman of the Board
341.00
--
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
18.00
--
Dr. Martin S. Goldstein, M.D.
Dr. Martin S. Goldstein, M.D.
Independent Director
Independent Director
--
--
Mr. Thomas R. Mika
Mr. Thomas R. Mika
Independent Director
Independent Director
--
-100.00%
Mr. Brian M. Murphy
Mr. Brian M. Murphy
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
2.45M
95.78%
Other
46.00K
1.80%
Australia
29.00K
1.13%
Europe
17.00K
0.66%
New Zealand
12.00K
0.47%
Israel
4.00K
0.16%
By Business
By Region
No Data
Shareholder
Update time: Fri, May 16
Update time: Fri, May 16
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Alpha Capital Aktiengesellschaft
4.37%
Morgan Stanley & Co. LLC
1.79%
Besser (Doron M.D.)
0.90%
UBS Financial Services, Inc.
0.68%
Tower Research Capital LLC
0.13%
Other
92.13%
Shareholder Statistics
Shareholder
Proportion
Alpha Capital Aktiengesellschaft
4.37%
Morgan Stanley & Co. LLC
1.79%
Besser (Doron M.D.)
0.90%
UBS Financial Services, Inc.
0.68%
Tower Research Capital LLC
0.13%
Other
92.13%
Type
Shareholder
Proportion
Holding Company
4.37%
Individual Investor
0.99%
Hedge Fund
0.79%
Investment Advisor
0.68%
Investment Advisor/Hedge Fund
0.01%
Other
93.16%
Institutional Shareholding
Update time: Tue, Mar 4
Update time: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
25
56.64K
7.46%
-1.57K
2024Q4
29
390.46K
7.75%
-206.57K
2024Q3
31
421.26K
15.22%
+83.76K
2024Q2
31
243.60K
8.84%
-214.51K
2024Q1
34
373.91K
18.23%
+170.33K
2023Q4
38
117.62K
5.71%
-262.96K
2023Q3
41
131.29K
7.90%
-1.54K
2023Q2
41
49.26K
2.96%
-111.70K
2023Q1
41
69.83K
4.25%
-82.42K
2022Q4
43
125.58K
7.66%
-1.44K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Besser (Doron M.D.)
6.82K
0.9%
+6.82K
--
Feb 14, 2025
UBS Financial Services, Inc.
3.75K
0.49%
+3.61K
+2.68K%
Dec 31, 2024
Tower Research Capital LLC
550.00
0.07%
-1.00
-0.18%
Dec 31, 2024
Jacob (Harold)
348.00
0.05%
--
--
Jan 17, 2025
Fashek (Christopher M)
341.00
0.04%
--
--
Feb 14, 2025
Northern Trust Investments, Inc.
102.00
0.01%
+102.00
--
Dec 31, 2023
Brown (Stephen Russell)
18.00
0%
--
--
Feb 14, 2025
Cassirer (Aurora)
9.00
0%
--
--
Feb 14, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Date
Type
Ratio
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 25, 2025
Merger
11<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
Feb 08, 2023
Merger
20<1
